ASC41 + phenytoin

ASC41 + phenytoin is a combination of two pharmaceutical agents administered together during clinical pharmacokinetic and drug-drug interaction studies. **ASC41** is a small molecule, liver-targeted prodrug that is metabolized by CYP3A4 to its active metabolite ASC41-A, a potent and selective thyroid hormone receptor β (THR-β) agonist. It is being developed for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)[1][2]. **Phenytoin** is an established anti-seizure (anticonvulsant) medication that stabilizes neuronal membranes primarily by blocking voltage-gated sodium channels[4][3]. In combination, ASC41 is investigated for potential interactions with phenytoin, a strong CYP3A4 inducer. Clinical data indicate that phenytoin does not cause clinically significant changes in ASC41 or its active metabolite's exposure, suggesting low risk for clinically meaningful drug-drug interaction between these agents[1][2].